Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome
Advances asset in the neuro-endocrine orphan disease space SCOUT-015 clinical trial currently has 9 activated…
Month: July 2022
Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels™ in the Treatment of Vascular Trauma
Thursday, July 14, 2022 @ 11:30 a.m. ET DURHAM, N.C., July 07, 2022 (GLOBE NEWSWIRE)…
Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
NEW YORK and LONDON, July 07, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors
NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) — Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic pharmaceutical…
IgA Nephropathy Takes Center Stage with Various Patient and Payer Events in July
NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) — As part of its ongoing commitment to…
Longeveron Announces Abstract Accepted for Presentation at the Alzheimer’s Association International Conference (AAIC)
MIAMI, July 07, 2022 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company…
Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financing
Uplisting is the Next Significant Step FRAMINGHAM, Mass., July 07, 2022 (GLOBE NEWSWIRE) — Arch…
SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009
The Company Continues to Evaluate Optimal Dosing for Patients with Acute Myeloid Leukemia and Lymphoma…
iSpecimen Adds New Global Biospecimen Suppliers to Proprietary Marketplace Platform for Researchers to Leverage
New Suppliers Will Increase Access to Unique Banked Biospecimens for Advancing Oncology and Cardiovascular Disease…
Avicanna Completes its First Commercial Export of its Derma-Cosmetics Brand Pura H&W™ into the European Union
Avicanna News Avicanna News The exclusive distribution agreement with Bio-Gate AG includes 5 SKUs from…
Theratechnologies to Announce Second Quarter 2022 Financial Results and Provide Business Update
MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a…
Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)
OCA 25 mg met the agreed primary endpoint of improvement in liver fibrosis without worsening…
Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings
– Multiple Podium and Poster Presentations on XIPERE® and Gene Therapy Delivery Utilizing SCS Microinjector®…
TScan Therapeutics Appoints Debora Barton, M.D., as Chief Medical Officer
Debora Barton Debora Barton WALTHAM, Mass., July 07, 2022 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc….
XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)
CALGARY, Alberta, July 07, 2022 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”)…
Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022
SEATTLE and CAMBRIDGE, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq:…
EvolveImmune Therapeutics Appoints Jay Fine, Ph.D., as President of Research and Development
Over 30 Years of Leadership in Drug Discovery and Development, Translational Sciences and Biomarker Research…
MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers
EscharEx Showed Safe, Effective and Rapid Debridement in VLUs and DFUsData Demonstrates EscharEx Reduced Wound…
Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X Conference
DEVON, Pa., July 07, 2022 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader…
RVL Pharmaceuticals plc Announces Preliminary Second Quarter 2022 UPNEEQ® Net Product Sales Results
— Expects second quarter 2022 preliminary UPNEEQ net product sales of approximately $8.4 million, representing…